Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

January 2022; 9 (1) ArticleOpen Access

Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8+ T-Cell Behaviors

Ana Carmena Moratalla, Yves Carpentier Solorio, Florent Lemaitre, Negar Farzam-kia, Annie Levert, Stephanie E.J. Zandee, Boaz Lahav, Jean Victor Guimond, View ORCID ProfileElie Haddad, Marc Girard, Pierre Duquette, View ORCID ProfileCatherine Larochelle, Alexandre Prat, View ORCID ProfileNathalie Arbour
First published December 6, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001119
Ana Carmena Moratalla
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anacarmena3@gmail.com
Yves Carpentier Solorio
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yves.carpentier.solorio@umontreal.ca
Florent Lemaitre
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: grdflo.lemaitre@gmail.com
Negar Farzam-kia
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: negarf.16@gmail.com
Annie Levert
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: annie.levert2@hotmail.com
Stephanie E.J. Zandee
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stephaniezandee@gmail.com
Boaz Lahav
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: boaz.lahav.chum@ssss.gouv.qc.ca
Jean Victor Guimond
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jeanvictorguimondjvg@gmail.com
Elie Haddad
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elie Haddad
  • For correspondence: elie.haddad@umontreal.ca
Marc Girard
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m_girard@videotron.ca
Pierre Duquette
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pierre.duquette.1@umontreal.ca
Catherine Larochelle
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catherine Larochelle
  • For correspondence: catherine.larochelle.med@ssss.gouv.qc.ca
Alexandre Prat
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: a.prat@umontreal.ca
Nathalie Arbour
From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathalie Arbour
Full PDF
Citation
Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8+ T-Cell Behaviors
Ana Carmena Moratalla, Yves Carpentier Solorio, Florent Lemaitre, Negar Farzam-kia, Annie Levert, Stephanie E.J. Zandee, Boaz Lahav, Jean Victor Guimond, Elie Haddad, Marc Girard, Pierre Duquette, Catherine Larochelle, Alexandre Prat, Nathalie Arbour
Neurol Neuroimmunol Neuroinflamm Jan 2022, 9 (1) e1119; DOI: 10.1212/NXI.0000000000001119

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
558

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1 ULBP4 Expression Is Elevated in Brain Lesions From Patients With MS

    (A) Relative mRNA expression of ULBP4 in postmortem brain samples from untreated patients with MS and controls (epilepsy) (Ctl) expressed as 2-ΔCt compared with 18S. Each dot represents 1 donor (n = 3 per group). Data are shown as mean + SEM. (B and C) Western blot analysis of ULBP4 in postmortem brain lysates from patients with MS and controls (Ctl). MS samples were characterized as active (A) MS lesion, chronic active (CA) MS lesion, NAWM, and NAGM. Control samples were dissected from either white or gray matter (WM/GM). (B) Representative Western blot showing ULBP4 and GAPDH detection in samples from 1 MS donor and 1 control as well as the positive control rhULBP4. (C) Quantification of 50 kDa (C.a) and 45 kDa (C.b) ULBP4 bands relative to GAPDH levels. Each dot represents 1 donor. Data are shown as mean for 5–6 patients with MS (5 untreated SPMS and 1 fingolimod-treated transitional RRMS-SPMS) and 6 controls. Comparison between different groups is indicated with lines: Kruskal-Wallis test and uncorrected Dunn test; *p < 0.05, **p < 0.01, and ***p < 0.001. CA = chronic active; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; MS = multiple sclerosis; NAGM = normal-appearing gray matter; NAWM = normal-appearing white matter; rhULBP4 = recombinant human ULBP4; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; ULBP4 = UL16-binding protein 4.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2 ULBP4 Is Mainly Expressed by Astrocytes in Brain Tissue From Patients With MS and Controls

    (A) Representative images for the costaining of ULBP4 (cyan) and GFAP (magenta) in paraffin-embedded sections from untreated MS donors (NAGM and WM lesion) and controls (no brain related disease); n = 4 for each group. Nuclei were stained with 4',6-diamidino-2-phenylindole (blue). Corresponding isotype controls are shown. Yellow arrows indicate ULBP4+GFAP+ cells, and red arrows indicate ULBP4-negative GFAP+ cells. Scale bars = 25 μM. (B) Representative enlarged image showing colocalization of GFAP and ULBP4 in the brain section. Scale bars = 10 µM. GFAP = glial fibrillary acidic protein; MS = multiple sclerosis; NAGM = normal-appearing gray matter; WM = white mater; ULBP4 = UL16-binding protein 4.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3 Several Types of Cellular Stress Increase the Proportion of ULBP4-Expressing Astrocytes

    (A–C) Flow cytometry analysis of ULBP4 expression by human astrocytes. (A) Gating strategy from 1 representative donor. Cell debris, doublets, and dead cells were excluded, and GFAP+ cells were selected for analysis. (B) Representative dot plots showing isotype control (B.a) or ULBP4 detection on living GFAP+ gated cells. Astrocytes were either kept under normal culture conditions (NIL) (B.b) or exposed to sodium arsenite (Na Arsenite) for 2 (B.c) and 6 hours (B.d). Percentage of ULBP4+ cells is indicated. (C) Quantification of ULBP4 expression on GFAP+ cells after exposure to sodium arsenite (C.a), tunicamycin (C.b), or proinflammatory cytokines (C.c). Each dot represents 1 donor. Data are shown as mean or mean +SEM, n = 7–9. Friedman test and Dunn multiple comparison test comparing NIL vs Na Arsenite or DMSO vs tunicamycin; 1-way analysis of variance comparing NIL vs cytokine *p < 0.05, **p < 0.01 ***p < 0.001. DMSO = dimethylsulfoxide; GFAP = Glial fibrillary acidic protein; MS = multiple sclerosis; IFNγ = interferon-γ; TNF = tumor necrosis factor; ULBP4 = UL16-binding protein 4.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4 Soluble ULBP4 Is Elevated in CSF From Female Patients With MS and Enhances Proinflammatory Properties of CD8+ T Lymphocytes

    (A and B) Western blot analysis of ULBP4 and albumin levels in CSF from patients with MS and controls (Ctl). (A) Representative Western blot including 5 untreated MS donors (1–5) and 2 controls (A and B) illustrating expression of ULBP4 and albumin. (B) Quantification of 45–50 kDa (B.a) and 25 kDa (B.b) bands of ULBP4 relative to albumin according to sex (♀: female; ♂: male) and disease (MS vs control). Each dot represents 1 donor. Mean ± SEM, n = 5 female untreated MS, n = 5 male untreated MS, n = 4 female controls, and n = 4 male controls. (C and D) Production of GM-CSF and IFNγ by CD8+ T lymphocytes stimulated with or without rhULBP4. (C) Diagram illustrating culture conditions: isolated CD8+ T lymphocytes were stimulated overnight with plate-bound anti-CD3 in the presence or absence of sULBP4 before collecting supernatants for ELISA measurements. (D) Quantification of secreted GM-CSF (D.a) and IFNγ (D.b) levels (pg/mL) in the presence (blue bars) or absence (white bars) of rhULBP4. Each dot represents 1 donor. Mean, n = 10 per group. Paired t test for GM-CSF production and Wilcoxon test for IFNγ production comparing NIL vs sULBP4; *p < 0.05 and **p < 0.01. GM-CSF = granulocyte-macrophage colony-stimulating factor; MS = multiple sclerosis; rhULBP4 = recombinant human ULBP4; sULBP4 = soluble UL16-binding protein 4; ULBP4 = UL16-binding protein 4.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5 Soluble ULBP4 Enhances the Motility of CD8+ T Lymphocytes

    (A–D) Time-lapse imaging of activated CD8+ T lymphocytes cocultured with human astrocytes in the presence or absence of sULBP4. (A) Diagram illustrating culture conditions. CD8+ T lymphocytes were activated overnight on anti-CD3 coated plates in the presence of anti-CD28 and interleukin-15, CFSE-labeled, and then added to astrocytes in the presence or absence of sULBP4 and imaged for 2 hours. (B) Three-dimensional time-lapse view at T = 0, T = 1, and T = 2 hours of activated CD8+ T lymphocytes (green) cocultured with astrocytes (magenta). (C and D) Analysis of the motility and behavior of CD8+ T lymphocytes from 3 untreated patients with MS and 3 sex- and age-matched healthy controls on coculture with astrocytes in the presence or absence of sUBLP4. Presented data are pooled from 3 independent experiments. (C) Coefficient of arrest (%) of individual CD8+ T lymphocytes; each dot represents 1 cell. Kruskal-Wallis test comparing sULBP4 vs NIL for each donors' group ****p < 0.0001. (D) Proportion of CD8+ T lymphocytes exhibiting the scanning, dancing, poking, and round behaviors when cocultured with astrocytes in the presence or absence of sULBP4. One way analysis of variance comparing NIL vs sULBP4 for each donors' group, *p < 0.05, **p < 0.01. CFSE = carboxyfluorescein succinimidyl ester; MS = multiple sclerosis; sULBP4 = soluble UL16-binding protein 4; ULBP4 = UL16-binding protein 4.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6 Proposed Involvement of the NKG2D Pathway in MS Pathology

    (A) CD8+ T lymphocytes can enter the CNS of patients with MS in part due to disrupted BBB. All infiltrating CD8+ T lymphocytes express NKG2D7 and thus can interact with ULBP4-expressing astrocytes including those having end feet in close proximity to the BBB. (B) Various cellular stresses (inflammation, ER stress, and oxidative stress) present in the brain of patients with MS can upregulate ULBP4 expression by astrocytes, as supported by our in vitro data. Reactive astrocytes, which are abundantly present in MS lesion, represent the predominant cell type expressing ULBP4 in the brain of patients with MS. (C) Soluble forms of ULBP4 are detectable in CSF; a soluble 25-kDa ULBP4 form is significantly elevated in CSF from female patients with MS compared with groups (male patients with MS and controls of both sexes). (D) Soluble ULBP4 can affect immune cell functions. On contact with sULBP4, CD8+ T lymphocytes increase their secretion of GM-CSF and IFNγ. Moreover, addition of sULBP4 to CD8+ T lymphocytes cocultured with astrocytes increases their motility and favors kinapse-like behaviors, which are more dynamic and may lead to enhanced displacement within the tissue. BBB = blood-brain barrier; ER = endoplasmic reticulum; MS = multiple sclerosis; sULBP4 = soluble UL16-binding protein 4.

Tables

  • Figures
  • Supplementary Materials
  • Table

Supplementary Materials

  • Figures
  • Tables
  • Video 1

    Download Supplementary Video 1 via http://dx.doi.org/10.1212/001119_Video_1

  • Video 2

    Download Supplementary Video 2 via http://dx.doi.org/10.1212/001119_Video_2

  • Video 3

    Download Supplementary Video 3 via http://dx.doi.org/10.1212/001119_Video_3

  • Video 4

    Download Supplementary Video 4 via http://dx.doi.org/10.1212/001119_Video_4

  • links.lww.com/NXI/A669

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • Autoimmune diseases
  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise